NLRP3 and myeloid sarcoma: There is substantial evidence indicating that NLRP3 inflammasome activation in MG contributes to MS pathogenesis and progression by recruiting activated T cells to the central nervous system (CNS) and promoting their cytokine release, leading to increased inflammation [94].